Lancashire (LRE) Competitors GBX 593 +6.00 (+1.02%) As of 07/11/2025 11:49 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesInsider TradesBuy This Stock LRE vs. MDC, ROAD, CCT, PRIM, CCS, EME, PHM, GEO, J, and MTHShould you be buying Lancashire stock or one of its competitors? The main competitors of Lancashire include Mediclinic International (MDC), Roadside Real Estate (ROAD), The Character Group (CCT), Primorus Investments (PRIM), Crossword Cybersecurity (CCS), Empyrean Energy (EME), Phimedix Plc (PHM.L) (PHM), Georgian Mining (GEO), Jacobs Engineering Group (J), and Mithras Investment Trust (MTH). These companies are all part of the "construction" industry. Lancashire vs. Its Competitors Mediclinic International Roadside Real Estate The Character Group Primorus Investments Crossword Cybersecurity Empyrean Energy Phimedix Plc (PHM.L) Georgian Mining Jacobs Engineering Group Mithras Investment Trust Mediclinic International (LON:MDC) and Lancashire (LON:LRE) are both construction companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations and media sentiment. Do analysts rate MDC or LRE? Lancashire has a consensus target price of GBX 663, suggesting a potential upside of 11.80%. Given Lancashire's stronger consensus rating and higher possible upside, analysts clearly believe Lancashire is more favorable than Mediclinic International.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mediclinic International 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Lancashire 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Do institutionals and insiders believe in MDC or LRE? 39.2% of Mediclinic International shares are owned by institutional investors. Comparatively, 60.5% of Lancashire shares are owned by institutional investors. 48.9% of Mediclinic International shares are owned by company insiders. Comparatively, 0.6% of Lancashire shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is MDC or LRE more profitable? Lancashire has a net margin of 37.12% compared to Mediclinic International's net margin of 4.99%. Lancashire's return on equity of 10.76% beat Mediclinic International's return on equity.Company Net Margins Return on Equity Return on Assets Mediclinic International4.99% 5.50% 2.30% Lancashire 37.12%10.76%6.75% Does the media refer more to MDC or LRE? In the previous week, Lancashire had 4 more articles in the media than Mediclinic International. MarketBeat recorded 4 mentions for Lancashire and 0 mentions for Mediclinic International. Mediclinic International's average media sentiment score of 1.17 beat Lancashire's score of -0.08 indicating that Mediclinic International is being referred to more favorably in the media. Company Overall Sentiment Mediclinic International Positive Lancashire Neutral Which has more risk and volatility, MDC or LRE? Mediclinic International has a beta of 0.42, meaning that its stock price is 58% less volatile than the S&P 500. Comparatively, Lancashire has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500. Is MDC or LRE a better dividend stock? Mediclinic International pays an annual dividend of GBX 3 per share. Lancashire pays an annual dividend of GBX 18 per share and has a dividend yield of 3.0%. Mediclinic International pays out 1,304.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Lancashire pays out 34.3% of its earnings in the form of a dividend. Lancashire is clearly the better dividend stock, given its higher yield and lower payout ratio. Which has preferable valuation and earnings, MDC or LRE? Lancashire has lower revenue, but higher earnings than Mediclinic International. Mediclinic International is trading at a lower price-to-earnings ratio than Lancashire, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMediclinic International£3.38B0.00£169M£0.23N/ALancashire£536.12M3.34£199.02M£52.4911.30 SummaryLancashire beats Mediclinic International on 13 of the 17 factors compared between the two stocks. Get Lancashire News Delivered to You Automatically Sign up to receive the latest news and ratings for LRE and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LRE vs. The Competition Export to ExcelMetricLancashireInsurance IndustryFinancial SectorLON ExchangeMarket Cap£1.79B£3.01B£6.16B£3.00BDividend Yield0.19%1.22%4.21%5.02%P/E Ratio11.305.7613.27150.83Price / Sales3.34122.011,738.23314,599.95Price / Cash2.172.04128.1027.97Price / Book0.971.561.914.58Net Income£199.02M£474.99M£1.23B£5.90B7 Day Performance1.37%-0.78%11.18%11.51%1 Month Performance4.59%6.92%7.30%8.27%1 Year Performance-2.79%16.36%17.74%32.75% Lancashire Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LRELancashire3.2934 of 5 starsGBX 593+1.0%GBX 663+11.8%-2.8%£1.79B£536.12M11.30393News CoverageAnalyst ForecastMDCMediclinic InternationalN/AN/AN/AN/A£3.69B£3.38B2,178.261,640News CoverageROADRoadside Real EstateN/AGBX 50.10-2.2%N/A+339.2%£69.37M£416.20K1.603,790CCTThe Character GroupN/AGBX 274+1.5%N/A-11.4%£50.64M£116.84M9.701,540Dividend IncreasePRIMPrimorus InvestmentsN/AGBX 3.25+3.2%N/A+13.4%£4.55MN/A4.9012,800Gap UpHigh Trading VolumeCCSCrossword CybersecurityN/AN/AN/AN/A£1.95M£4.19M-43.751,540News CoverageGap DownHigh Trading VolumeEMEEmpyrean EnergyN/AGBX 0.02-5.0%N/A-93.4%£769KN/A-0.0135,500Gap DownPHMPhimedix Plc (PHM.L)N/AN/AN/AN/A£327KN/A-1.586,520Gap DownHigh Trading VolumeGEOGeorgian MiningN/AGBX 0.16+11.4%N/A-86.7%£209K£233.00K-0.0215,800News CoverageGap DownJJacobs Engineering GroupN/AN/AGBX 200+∞N/A£0.00N/A0.0060,000High Trading VolumeMTHMithras Investment TrustN/AN/AN/AN/A£0.00N/A0.001,920Gap Up Related Companies and Tools Related Companies Mediclinic International Competitors Roadside Real Estate Competitors The Character Group Competitors Primorus Investments Competitors Crossword Cybersecurity Competitors Empyrean Energy Competitors Phimedix Plc (PHM.L) Competitors Georgian Mining Competitors Jacobs Engineering Group Competitors Mithras Investment Trust Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:LRE) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lancashire Holdings Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Lancashire With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.